Document:

EX-10.12 Agreement with Donald Jasinski

 

Exhibit 10.12

CONSULTING AGREEMENT

Catalyst Pharmaceutical Partners, Inc. (hereinafter
“COMPANY”) and Dr. Donald Jasinski (hereinafter
“CONSULTANT”) 3 Barranco Court, Towson, MD 21204
agree that CONSULTANT will advise COMPANY on matters relating to
the field of clinical studies with vigabatrin to treat
cocaine/methamphetamine addiction (hereinafter
“Field”) under the following terms and conditions
(“this Agreement”):

		
	1.	
    Consulting Services. CONSULTANT’s responsibilities
    shall include, without limitation, the following activities
    (hereinafter collectively referred to as “Services”):

		
	 	
    Consult with Company with regard to clinical studies designed to
    test vigabatrin for the treatment of cocaine/methamphetamine
    abuse. Also, to serve on the Company’s Scientific Advisory
    Board.
	 
	 	
    The Services shall be performed via telephone and
    correspondence, and may include meetings with personnel and
    other consultants at times and locations to be mutually agreed
    upon. In each instance, CONSULTANT shall perform the Services
    only upon COMPANY’s request and after the scope of the
    Services has been approved by COMPANY.
	 
	 	
    The parties acknowledge that the Johns Hopkins University is not
    a party to this Agreement, which is a private contract between
    CONSULTANT and COMPANY. CONSULTANT and COMPANY also agree that
    the Johns Hopkins University, its Schools and Divisions, and the
    Johns Hopkins Hospital and Health System and its affiliated
    hospitals (hereinafter individually and collectively
    “JHU”) have no liability or responsibility to either
    party under this Agreement. The CONSULTANT’s office address
    at JHU may be identified in this Agreement for the purpose of
    convenient communication between COMPANY and CONSULTANT and does
    not in any way alter the fact that this is a private agreement
    between COMPANY and CONSULTANT.
	 
	 	
    CONSULTANT represents and warrants that at the time of execution
    of this Agreement, the terms of this Agreement are not
    inconsistent with any other contractual or legal obligation.
    CONSULTANT may have or with the policies of any institution or
    company with which CONSULTANT is associated.
	 
	 	
    COMPANY and CONSULTANT recognize that CONSULTANT’s primary
    duty as a full-time JHU faculty member is to JHU. COMPANY and
    CONSULTANT also agree that JHU policies and CONSULTANT’s
    obligations to JHU shall govern and be afforded primacy in the
    event a conflict arises between such policies and obligations
    and this Agreement. CONSULTANT shall promptly notify COMPANY in
    the event CONSULTANT becomes aware of a conflict between such
    policies and obligations and this Agreement, to the extent that
    such notification does not breach confidentiality provisions or
    understandings regarding confidentiality between JHU and an
    actual or potential research sponsor or collaborator or other
    third party, or between CONSULTANT and any third party. COMPANY
    and CONSULTANT will jointly determine whether or not to
    terminate this Agreement as a result of aforementioned
    notification. Nothing in this Agreement shall in any way inhibit
    CONSULTANT’s ability to conduct academic research and other
    academic activities at, through, or on behalf of JHU, regardless
    of the sponsor or field of such activities, during or at any
    time after the term of this Agreement.

 

		
	 	
    If CONSULTANT believes that consulting services she/he provides
    for other parties under a private agreement or arrangement to
    which JHU is not a party may be inconsistent with the terms of
    this Agreement, CONSULTANT shall promptly notify COMPANY, to the
    extent that such notification does not breach confidentiality
    provisions or undertakings between CONSULTANT and any third
    party. COMPANY and CONSULTANT will jointly determine whether or
    not to terminate this Agreement as a result of aforementioned
    notification.
	 
	 	
    CONSULTANT shall not use the facilities, equipment, materials,
    funds, or resources owned or administered by JHU, or located on
    any of the premises thereof; or engage or employ students,
    trainees, post-doctoral fellows or other employees thereof, to
    provide services under this Agreement. CONSULTANT may disclose
    to COMPANY under this Agreement any information that she/he
    would normally freely disclose to other members of the
    scientific community at large, whether by publication, by
    presentation at seminars, or in informal scientific discussions,
    but CONSULTANT shall not disclose under this Agreement:
    (a) information that is proprietary to JHU and not
    generally available to the public other than through formal
    institutional transactions; or (b) unpublished results of,
    or data from, research or clinical activity conducted at, by, or
    on behalf of JHU. COMPANY understands that in providing services
    under this Agreement, CONSULTANT may inadvertently disclose
    proprietary information of JHU to COMPANY. COMPANY agrees that
    in the event CONSULTANT discloses proprietary information of JHU
    under this Agreement, CONSULTANT has the right to so notify
    COMPANY in writing within thirty (30) days of disclosure of
    such information. COMPANY agrees not to disclose or use the
    information in any way in the event of such notification.
    Nothing in this Agreement in any way alters the terms of any
    agreements to which JHU is a party, existing prior to the
    effective date of this Agreement, or prepared and finalized
    after the effective date of this Agreement.

		
	2.	
    Compensation. In consideration for CONSULTANT’s
    services hereunder, COMPANY shall pay CONSULTANT as follows:
    [Complete only the applicable sections.]

			
	 	a) 	
    $18,000.00 per year, paid monthly.
	 
	 	b) 	
    12,000 company stock options, with an exercise price of $2.00
    per share and vesting as follows: 3,000 shares quarterly.
    COMPANY will ask CONSULTANT to sign a separate stock option
    agreement.
	 
	 	c) 	
    Reasonable out-of-pocket expenses (upon presentation of
    appropriate receipts) incurred by CONSULTANT, including all
    travel, food and lodging, in connection with the Services
    provided hereunder.

		
	 	
    Payment shall be made within forty five (45) days of
    receipt of an invoice of itemized services and submission of
    appropriate vouchers and receipts as may be reasonably necessary
    to substantiate CONSULTANT’s out-of-pocket expenses.

 

		
	 	
    CONSULTANT shall not be paid vacation, holiday or sick time
    during the term of Agreement. In the event of premature
    termination of the Agreement COMPANY shall pay CONSULTANT for
    the Services performed and expenses incurred through the date of
    termination. In the event of any overpayment by COMPANY,
    CONSULTANT shall, upon submission by COMPANY of documents
    evidencing such overpayment, remit the same to COMPANY within
    thirty (30) days after termination. CONSULTANT shall also
    cooperate with COMPANY in producing documents as evidence of
    overpayment of either party.

		
	3. 	
    Term and Termination. This Agreement shall be effective
    upon full execution of this Agreement and continue for a period
    of (complete applicable box):

		
	 	
    1 year
	 
	 	
    The Agreement may be extended by written agreement signed by the
    parties. Either party may terminate this Agreement with or
    without cause upon giving thirty (30) days prior written
    notice to the other party. Termination or expiration of this
    Agreement shall not affect any rights or obligations which have
    accrued prior thereto or in connection therewith. Any written
    agreements altering the term and/or conditions of this agreement
    must be reviewed and approved in advance by the Johns Hopkins
    University School of Medicine’s Office of Policy
    Coordination.

4. Confidential Information

		
	4a. 	
    With respect to any technical or business information of a
    proprietary or confidential nature which CONSULTANT may obtain
    from COMPANY under this Agreement or which is developed by
    CONSULTANT as a result of CONSULTANT’s Services hereunder
    (all of such technical and business information being referred
    to hereinafter as “Company Information”), it is
    understood that unless disclosure or use provided by COMPANY; or
    (b) is covered under a separate written agreement between
    JHU and COMPANY, CONSULTANT will for a period of three
    (3) years from the date of disclosure hereunder:

			
	 	i)	
    treat Company Information as confidential;
	 
	 	ii)	
    not use any Company Information except as and to the extent
    necessary for the aforesaid consulting tasks; and
	 
	 	iii)	
    not disclose any Company Information to any third party without
    prior written approval from COMPANY.

 

		
	4b. 	
    Consultant’s objections set forth in this Section 4
    shall not apply with respect to any portion of the Company
    Information that:

			
	 	i)	
    was in the public domain at the time it was communicated to
    CONSULTANT under this Agreement;
	 
	 	ii)	
    entered the public domain through no breach of this Agreement by
    CONSULTANT, subsequent to the time it was communicated to
    CONSULTANT under this Agreement;
	 
	 	iii)	
    was in CONSULTANT’s possession to the best of
    CONSULTANT’s knowledge free of any obligation of confidence
    at the time it was communicated to CONSULTANT under this
    Agreement;
	 
	 	iv)	
    was rightfully communicated to CONSULTANT free of any obligation
    of confidence subsequent to the time it was communicated to
    CONSULTANT under this Agreement;
	 
	 	v)	
    was developed by CONSULTANT independently of and without
    reference to any information communicated to CONSULTANT under
    this Agreement;
	 
	 	vi)	
    is required to be disclosed in response to a valid order by a
    court or other governmental body, or as otherwise required by
    law.

		
	4c. 	
    Notwithstanding the above, prior to any subcontracting to third
    parties, such third party must be bound to the same obligations
    as under this Agreement regarding any Confidential Information
    prior to disclosure.
	 
	5. 	
    Publications. CONSULTANT shall not publish, nor submit
    for publication, any work resulting from the Services provided
    hereunder without prior written approval from COMPANY. If
    CONSULTANT publishes or submits for publication work resulting
    from the Services provided hereunder, CONSULTANT shall include
    the following statement in the publication: “Dr. [Faculty
    name] is a paid consultant to [Company name].” Nothing in
    this agreement shall be construed as prohibiting or otherwise
    limiting CONSULTANT’s ability to publish, submit for
    publication, or otherwise disclose the results of
    CONSULTANT’s activities as a faculty member of JHU, during
    or at any time after the term of this Agreement.
	 
	6.  	
    Publicity. With the limited exception of citing
    CONSULTANT’S faculty title (subject to the conditions
    outlined below), COMPANY and its affiliates will not use the
    names, likenesses, or logos of the JHU in any of their
    fund-raising or investment documents, publications, websites,
    advertisements, press releases, or marketing and promotional
    materials (hereinafter “Materials”). If COMPANY cites
    Consultant’s title and/or affiliation with JHU in its
    Materials, it agrees to include the following statement in such
    Materials as a parenthetical comment next to the
    consultant’s name, title, and/or affiliation:
    “Participation by Dr. Donald R. Jasinski does not
    constitute or imply endorsement by the Johns Hopkins University
    or the Johns Hopkins Hospital and Health System.”

 

			
	 	7. 	
    Compliance. In the performance of the Services hereunder,
    CONSULTANT shall comply with all applicable federal, state and
    local laws, regulations and guidelines. CONSULTANT shall also
    comply with COMPANY’s policies when on COMPANY premises.
	 
	 	8. 	
    Independent Contractor. CONSULTANT’s status under
    this Agreement is that of an independent contractor. CONSULTANT
    shall not be deemed an employee, agent, partner or joint
    venturer of COMPANY for any purpose whatsoever, and CONSULTANT
    shall have no authority to bind or act on behalf of COMPANY.
    This Agreement shall not entitle CONSULTANT to participate in
    any benefit plan or program of COMPANY. CONSULTANT shall be
    responsible for, and agrees to comply with, obligations under
    federal and state tax laws for payment of income and, if
    applicable, self-employment tax.
	 
	 	9. 	
    Assignment. CONSULTANT may not assign this Agreement or
    any interest herein, or delegate any of its duties hereunder, to
    any third party without COMPANY’s prior written consent,
    which consent is within COMPANY’s sole discretion to grant
    or withhold. Any attempted assignment or delegation without such
    consent shall be null and void.

		
	10. 	
    Debarment. CONSULTANT warrants and represents that
    CONSULTANT has never been, if not currently, and, during the
    term of this Agreement, will not become:

			
	 	a) 	
    an individual who has been debarred by the U.S. Food and
    Drug Administration (“FDA”) pursuant to
    21 U.S.C. 335a (a) or (b) (“Debarred
    individual”) from providing services in any capacity to a
    person that has an approved or pending drug product application,
    or an employer, employee or partner of a Debarred Individual or
	 
	 	b) 	
    a corporation, partnership or association that has been debarred
    by the FDA pursuant to 21 U.S.C. 335a (a) or (b)
    (“Debarred Entity”) from submitting or assisting in
    the submission of any abbreviated drug application, or an
    employee, partner, shareholder, member, subsidiary or affiliate
    of a Debarred Entity.

		
	 	
    CONSULTANT further warrants and represents that no Debarred
    Individual or Debarred Entity has performed or rendered, or will
    perform or render, any services of assistance relating to
    activities taken pursuant to this Agreement. CONSULTANT further
    warrants and represents that CONSULTANT has no knowledge of any
    circumstances which may affect the accuracy of the foregoing
    warranties and representations, including, but not limited to,
    FDA investigation of, or debarment proceedings against
    CONSULTANT or any person or entity performing services or
    rendering assistance relating to activities taken pursuant to
    this Agreement, and CONSULTANT will immediately notify COMPANY
    if CONSULTANT becomes aware of any such circumstances during the
    term of this Agreement.

 

		
	11. 	
    Entire Agreement. This Agreement contains the entire
    understanding of the parties with respect to the matters herein
    contained and supersedes all previous agreements and
    undertakings with respect thereto. This agreement may be
    modified only by written agreement signed by the parties.

		
	 	
    This Agreement shall be governed by and construed in accordance
    with the laws of the State of Florida without regard to its
    conflicts of laws rules.

CATALYST PHARMACEUTICAL PARTNERS, INC.

220 Miracle Mile, Suite 234

Coral Gables, Florida 33134

			
	By: 	
                             /s/ Patrick
    J. McEnany	 

		
	
     
	 
	
                             Patrick
    J. McEnany
    	 

		
	Date: 	
                             2/10/06

 

Donald R. Jasinski, M.D.

John Hopkins University Medical Center

Mason Lord Building

West Tower, 2nd Floor

4940 Eastern Avenue

Baltimore, Maryland 21224

			
	By: 	

                         /s/ Donald
R. Jasinski	 

		
	
     
	 

			
	Date: 	
                             3/10/06EX-10.13 Agreement with Charles Gorodetzky

 

Exhibit 10.13

AGREEMENT

     This AGREEMENT (this “Agreement”) is made and entered into this 25th day of August, 2006,
effective the 1st day of September, 2006 (the “Effective Date”) by and between CATALYST
PHARMACEUTICAL PARTNERS, INC., a Delaware corporation, with offices located in Coral Gables,
Florida (the “Company”) and CHARLES W. GORODETZKY, M.D., Ph.D., an individual resident of the state
of Missouri (“Gorodetzky”).

     In consideration of the mutual representations, warranties, covenants and agreements contained
in this Agreement, the parties hereto agree as follows:

	 	1.	 	Services. Throughout the term of the Agreement, Gorodetzky shall act as the
Chief Medical Officer of the Company.

Gorodetzky represents and warrants that, at the time of execution of this Agreement, the terms
of this Agreement are not inconsistent with any other contractual or legal obligation Gorodetzky
may have or the policies of any institution or company with which Gorodetzky is associated. If
Gorodetzky believes that consulting services he provides for other parties under a private
arrangement may be inconsistent with the terms of this Agreement, Gorodetzky shall properly notify
the Company, to the extent that such notification does not breach confidentiality provisions or
understandings between Gorodetzky and any third party. The Company and Gorodetzky will jointly
determine whether or not to terminate this Agreement as a result of the aforementioned
notification.

	 	2.	 	Compensation. In consideration for Gorodetzky’s services hereunder, the
Company shall pay Gorodetzky as follows:

	 	a.	 	an hourly rate of $250.00 per hour. Gorodetzky is guaranteed a minimum
of 120 hours per 12-week quarter (or 40 hours per four-week billing period). Hours
above 120 hours per 12-week quarter will be billed at a rate of $200.00 per hour.
	 
	 	b.	 	15,000 options (the “Options”) to purchase shares of the Company’s
common stock at an exercise price equal to the price at which the Company completes
its Initial Public Offering, which Options shall vest over a three-year period on
the following schedule:

September 1, 2007: 5,000 options

September 1, 2008: 5,000 options (10,000 in the aggregate)

September 1, 2009: 5,000 options (15,000 in the aggregate)

The Options will be issued pursuant to the Company’s 2006 Stock Incentive Plan;

	 	c.	 	Any travel by Gorodetzky for Company purposes will be reimbursed,
provided that original receipts are submitted for all costs over $25.00. Domestic
air travel (U.S. and Canada) will be by coach only. International air travel will
be by

 

 

	 	 	 	business class. Travel time, door-to-door, will be reimbursed at half Gorodetzky’s
rate described in Section 2(a) above. If Gorodetzky chooses to use private
automobile travel for business travel purposes, the reimbursed cost and accrued time
will not exceed that what would be reasonably expected using airplane travel. Other
directly related business expenses over $10.00 will be billed with submission of
original receipts.

	 	d.	 	For purposes of this Agreement, Gorodetzky is termed an independent
contractor of the Company. Gorodetzky shall be responsible for, and agrees to
comply with, obligations under federal and state tax laws for payment of all income
taxes. All payments made to Gorodetzky will be reported using a IRS 1099 form or
similar form. All invoices must be paid within 30 days of receipt of such bill.
	 
	 	e.	 	Gorodetzky will submit an invoice for work performed every four weeks
for 40 hours for that four-week billing period. Additional hours over the 120 hour
per quarter minimum will be billed at the end of each 12-week period. Any unused
hours in a four-week billing period will carry over into the next four-week billing
period (unless accrued in the last four-week period of the quarter). Such unused
hours will be deemed “short-term carryover hours” and, if not used in the 12-week
quarter in which they accrued, will expire and be cancelled at the end of that
12-week quarter. Any unused hours accrued because of unavailability of Gorodetzky
for more than one week will be termed “long-term carryover hours” and will carry
forward for the full contract period.
	 
	 	 	 	If not used by the end of the contract period, long-term carryover hours will expire
and be cancelled. If both short-term and long-term carryover hours exist in the same
12-week billing quarter, short-term carryover hours will be used first. Time will be
accounted for in quarter-hour increments. If the actual billable time in any 12-week
billing quarter exceeds the guaranteed 120 hours by more than 20%, the parties agree
to renegotiate the compensation plan described above. Gorodetzky must provide, in
writing, via e-mail to the Company any vacations for one week or longer a minimum of
six weeks prior to the starting date of the vacation.

	 	3.	 	Term and Termination. This Agreement shall be effective September 1, 2006 and
will be effective for a period of 48 weeks, ending on August 2, 2007, unless earlier
terminated by either party via ten business days prior notice. Upon the expiration of this
Agreement, it will continue for an additional period of 48 weeks unless terminated by
either party with 10 days notice prior to the expiration of any period.
	 
	 	4.	 	Confidentiality. Gorodetzky agrees that at all times during the term of this
Agreement and after the termination of employment for as long as such information remains
non-public information, Gorodetzky shall (i) hold in confidence and refrain from disclosing
to any other party all information, whether written or oral, tangible or intangible, of a
private, secret, proprietary or confidential nature, of or concerning the Company or any of
its affiliates and their business and operations, and all files, letters,

2

 

	 	 	 	memoranda, reports, records, computer disks or other computer storage medium, data, models
or any photographic or other tangible materials containing such information (“Confidential
Information”), including without limitation, any sales, promotional or marketing plans,
clinical data or information about the Company’s product development efforts, programs,
techniques, practices or strategies, or future development plans (including existing and
entry into new geographic and/or product markets), and any customer lists, (ii) use the
Confidential Information solely in connection with his employment with the Company or any of
its affiliates and for no other purpose, (iii) take all precautions necessary to ensure that
the Confidential Information shall not be, or be permitted to be, shown, copied or
disclosed to third parties, without the prior written consent of the Company or any of its
affiliates, and (iv) observe all security policies implemented by the Company or any of its
subsidiaries or affiliates from time to time with respect to the Confidential Information.
In the event that Gorodetzky is ordered to disclose any Confidential Information, whether in
a legal or regulatory proceeding or otherwise, Gorodetzky shall provide the Company or any
of its affiliates with prompt notice of such request or order so that the Company or any of
its subsidiaries or affiliates may seek to prevent disclosure. In addition to the foregoing
Gorodetzky shall not at any time libel, defame, ridicule or otherwise disparage the Company.
	 
	 	 	 	Gorodetzky agrees that all work done in the name of or on behalf of the Company is deemed the
property of the Company pursuant to this Agreement.

	 	5.	 	Notices. All notices, requests, demands, claims and other communications
hereunder shall be in writing and shall be deemed given if delivered by certified or
registered mail (first class postage pre-paid), guaranteed overnight delivery or facsimile
transmission if such transmission is confirmed by delivery by certified or registered mail
(first class postage pre-paid) or guaranteed overnight delivery to, the following addresses
and telecopy numbers (or to such other addresses or telecopy numbers which such party shall
designate in writing to the other parties): (a) if to the Company, at its principal
executive offices, addressed to the Chief Executive Officer, with a copy to Philip B.
Schwartz, Esq., Akerman, Senterfitt & Eidson, P.A., One Southeast Third Avenue, Miami,
Florida 33131; and (b) if to Gorodetzky, at the address listed on the signature page
hereto.
	 
	 	6.	 	Amendment; Waiver. This Agreement may not be modified, amended, supplemented,
canceled or discharged, except by written instrument executed by all parties. No failure
to exercise, and no delay in exercising, any right, power or privilege under this Agreement
shall operate as a waiver, nor shall any single or partial exercise of any right, power or
privilege hereunder preclude the exercise of any other right, power or privilege. No
waiver of any breach of any provision shall be deemed to be a waiver of any preceding or
succeeding breach of the same or any other provision, nor shall any waiver be implied from
any course of dealing between the parties. No extension of time for performance of any
obligations or other acts hereunder or under any other agreement shall be deemed to be an
extension of the time for performance of any other obligations or any other acts. The
rights and remedies of the parties under this Agreement are in addition to all other rights
and remedies, at law or equity, that they may have against each other.

3

 

	 	7.	 	Assignment; Third Party Beneficiary. This Agreement, and Gorodetzky’s rights
and obligations hereunder, may not be assigned or delegated by Gorodetzky. The Company may
assign its rights, and delegate its obligations, hereunder to any affiliate of the Company
or any successor or assign. The rights and obligations of the Company under this Agreement
shall inure to the benefit of and be binding upon its respective successors and assigns.
	 
	 	8.	 	Severability; Survival. In the event that any provision of this Agreement is
found to be void and unenforceable by a court of competent jurisdiction, then such
unenforceable provision shall be deemed modified so as to be enforceable (or if not subject
to modification then eliminated herefrom) for the purpose of those procedures to the extent
necessary to permit the remaining provisions to be enforced. The provisions of Section 4
will survive the termination for any reason of Gorodetzky’s relationship with the Company.
	 
	 	9.	 	Counterparts. This Agreement may be signed in any number of counterparts, each
of which shall be an original but all of which together shall constitute one and the same
instrument.
	 
	 	10.	 	Governing Law. This Agreement shall be construed in accordance with and
governed for all purposes by the laws of the State of Florida applicable to contracts
executed and to be wholly performed within such State.
	 
	 	11.	 	Entire Agreement. This Agreement contains the entire understanding of the
parties in respect of its subject matter and supersedes all prior agreements and
understandings (oral or written) between or among the parties with respect to such subject
matter.

[ Signatures on Following Page]

4

 

     IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be
made this 1st day of
September, 2006.

	 	 	 	 	 
	 	 	 
	 	
/s/ Charles Gorodetzky
 	 
	 	Charles Gorodetzky 
 	 
	 	Address for Notices: 	 
	 
	 	 	 
	 	 	 
	 
	 	 	 
	 	
 	 
	 
	 	 	 
	 	
 	 
	 
	 	 	 
	 	
 	 
	 	 	 
	 
	 	COMPANY

 	 
	 	/s/
Patrick J. McEnany
 	 
	 	Patrick J. McEnany 	 
	 	Chief Executive Officer 	 
	 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]